"This services agreement extends over four years and covers LymPro’s central laboratory requirements under CLIA (under CLIA, only 1 laboratory facility can run a Laboratory Developed Test), in addition to consulting support for Eltoprazine’s further clinical development and our MANF program as we move it towards human trials. With this agreement, we also gain access to a global distribution network for LymPro, including central laboratories in Europe, Singapore, India and China that will allow LymPro to enter these new markets seamlessly through an already established distribution framework."

Pretty clear to me that BP didn't offer enough for a piece of LymPro, and GC continues to hold the reins. IMO ICON will not become a financial "partner", but has only signed on to be the central laboratory under CLIA (a huge opportunity for them).

As that process moves forward, it will become clear to the world that LymPro works as GC has said...and the world is watching!

The "financial" partner will be signed when a suitable figure is obtained...and we will all win! That this only involves LymPro and AMBS has so much else going on in other areas makes this the most exciting investment I have seen!

All In, Go AMBS
VO